


## Dr. Lal PathLabs strengthens genomics capabilities with Illumina's NovaSeq X Series

25 June 2025 | News

### NovaSeq™ X system features Illumina's cutting-edge XLEAP-SBS™ chemistry



Dr. Lal PathLabs has expanded its genomics capabilities by adding Illumina's NovaSeq™ X Series to its dedicated genomics division, Genevolve. With the integration of Illumina's latest technology, Dr. Lal PathLabs can now deliver faster and more accurate genomic research insights.

The NovaSeq™ X system features Illumina's cutting-edge XLEAP-SBS™ chemistry, offering unmatched throughput, accuracy, and sustainability. The NovaSeq X Plus can generate more than 20,000 whole genomes per year, more than double the throughput of Illumina's previous sequencers. Its unprecedented speed, scale, and accuracy push the limits of what's possible in genetic sequencing. And its powerful technology allows users to unlock previously unimaginable discoveries and advancements.

Launched in 2019, Genevolve has swiftly emerged as a DNA-based center of excellence. The addition of Illumina products further strengthens Genevolve's position as a pioneer in next-generation sequencing (NGS), enabling Dr. Lal PathLabs deliver actionable, AI-powered insights with greater speed and sensitivity.

"As Illumina continues to grow in India, we are committed to democratising access to sequencing technologies", said Gregory Essert, General Manager, Emerging Markets, Illumina. "NovaSeq X Series represents our leadership in next-generation

sequencing, and we are pleased to see it being adopted by institutions like Dr. Lal PathLabs, which are at the forefront of driving scientific discovery and access to genomic insights in India. We hope this empowers them to reach their goals more quickly.”

Dr. Lal PathLabs Limited and Illumina aim to engage closely with India’s medical and scientific communities to build awareness and capacity for genomics-based decision-making.